The Protective Effects of Apigenin Against Radiation‐Induced Intestinal Injury. Issue 3 (12th July 2022)

• Record Type: Journal Article
• Authors: Liu, Danjie; Peng, Renjun; Chen, Zhongmin; Yu, Huijie; Wang, Sinian; Dong, Suhe; Li, Wei; Shao, Wen; Dai, Jing; Li, Fengsheng; Jiang, Qisheng; Sun, Wanjun
• Is Part Of: Dose-response. Volume 20:Issue 3(2022)
• Publication Date: 2022-07-12
• Subjects: apigenin -- radioprotector -- radiation-induced intestinal injury -- Nrf2; Dose-response relationship (Biochemistry) -- Periodicals; Drugs -- Dose-response relationship -- Periodicals; Drugs -- Physiological effect -- Periodicals; Hormesis -- Periodicals; Dose-Response Relationship, Drug -- Periodicals; Dose-response relationship (Biochemistry); Drugs -- Dose-response relationship; Drugs -- Physiological effect; Periodicals; 571.634
• DOI: 10.1177/15593258221113791
• Languages: English
• ISSNs: 1559-3258

Abstract

Radiation-induced intestinal injury (RIII) restricts the therapeutic efficacy of radiotherapy in abdominal or pelvic malignancies. Also, intestinal injury is a major cause of death following exposure to high doses of radiation in nuclear accidents. No safe and effective prophylactics or therapeutics for RIII are currently available. Here, we reported that the apigenin, a natural dietary flavone, prolonged the survival in c57 mice after lethal irradiation. Apigenin pretreatment brought about accelerated restoration of crypt-villus structure, including enhanced regenerated crypts, more differentiated epithelium cells, and increased villus length. In addition, intestinal crypt cells in the apigenin-treated group exhibited more proliferation and less apoptosis. Furthermore, apigenin increased the expression of Nrf2 and its downstream target gene HO-1, and decreased oxidative stress after irradiation. In conclusion, our findings demonstrate the radioprotective efficacy of apigenin. Apigenin has the potential to be used as a radioprotectant in cancer therapy and nuclear accidents.